Cascadian Therapeutics Inc (USA) news

   Watch this stock
Showing stories 1 - 10 of about 81   

Articles published

CASC 1.15 -0.04 (-3.36%)
price chart
Company Update (NASDAQ:CASC): Cascadian Therapeutics Inc (USA) Announces ...
Cascadian Therapeutics Inc (USA) (NASDAQ:CASC), a clinical-stage biopharmaceutical company, announced that the United States Adopted Names (USAN) Council and the International Nonproprietary Names (INN) Expert Group have approved the ...
Company Update (NASDAQ:CASC): Cascadian Therapeutics Inc (USA) Announces ...
casc Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) announced that it intends to offer and sell shares of its common stock in an underwritten public offering.
Stock Update (NASDAQ:CASC): Cascadian Therapeutics Inc (USA) Receives ONT-380 ...
Cascadian Therapeutics (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that the ONT-380 program in advanced HER2+ metastatic breast cancer has received Fast Track designation from the U.S. Food and Drug ...
Cascadian boosted by FDA fast track for cancer drug  Proactive Investors USA & Canada
Cascadian's lead product candidate Fast Track'd for subtype of ...  Seeking Alpha
Oncothyreon (ONTY) Changes Name to Cascadian Therapeutics; Will Begin Trading ...
Oncothyreon Inc. (Nasdaq: ONTY) (Nasdaq: CASC) announced that the Company is changing its name to Cascadian Therapeutics, Inc. and will trade on the NASDAQ Global Select Market under the new ticker symbol “CASC,” effective at market open on ...
Oncothyreon Renames Itself Cascadian Therapeutics (NASDAQ:ONTY)  Sonoran Weekly Review
Oncothyreon Presents Phase 1b Results of ONT-380 in Combination with T-DM1 ...  GlobeNewswire (press release)
Biotech Beat: Analysts Weigh In On EXACT Sciences Corporation (EXAS ...
Exact shares rallied yesterday on an apparent leaked JAMA article unveiling that USPSTF highly recommends colon cancer screening from age 50 to 75, but will no longer rank tests; instead, it is providing a list of acceptable ones that includes FITDNA ...
BRIEF-Oncothyreon says company is changing its name to Cascadian Therapeut...
... stocks edged down on Thursday as appetite for risk was checked by weakness on Wall Street and caution ahead of a speech by Federal Reserve Chair Janet Yellen on Friday, an event global markets hope will provide clues on the outlook for U.S. rates.
Cascadian Therapeutics Says New Data Support Advancement of ONT-380 Study ...
Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) has declined 65.00% since November 5, 2015 and is downtrending. It has underperformed by 64.01% the S&P500.
Stocks Inside Traders Spotlight: Cascadian Therapeutics Inc (USA (NASDAQ:CASC ...
Cascadian Therapeutics Inc (USA (NASDAQ:CASC) went higher by +0.73% to close at $ 0.95. The company exchanged total volume of 676.67 thousand shares throughout course of last trade however it holds an average trading capacity of 1.13 million ...
Current Cascadian Therapeutics, Inc. (NASDAQ:CASC) PT Means Stock Is Worth ...
Cascadian Therapeutics, Inc. (NASDAQ:CASC) up 28.42 per cent in the past week, is under coverage of 5 analysts who collectively recommend a hold rating on stock.
NASDAQ Gainers: Cascadian Therapeutics, Inc. (NASDAQ:CASC), Century Aluminum ...  Benchmark Monitor
BRIEF-Cascadian Therapeutics announces approval of Tucatinib for lead prod...
WASHINGTON, Aug 31 The United States has accused the European Union of grabbing revenue intended for U.S. coffers when it ordered Apple Inc to pay up to $14.5 billion in back taxes, a decision that could cause friction at an international summit in ...